Overview

* CareDx ( CDNA ) Q3 revenue rose 21% yr/yr, beating analyst expectations

* Adjusted EPS for Q3 beats consensus, reflecting strong operational performance

* Company raised 2025 revenue guidance to $372 mln-$376 mln

Outlook

* CareDx ( CDNA ) raises 2025 revenue guidance to $372 mln to $376 mln

* Company increases 2025 adjusted EBITDA guidance to $35 mln to $39 mln

Result Drivers

* TESTING SERVICES - Testing services revenue increased 19% yr/yr, driven by a 13% rise in testing volume

* NEW PRODUCT LAUNCHES - Introduction of AlloSeq Tx11 and HistoMap Kidney supported revenue growth

* INNOVATION IN TRANSPLANT SOLUTIONS - New products like HistoMap Kidney and AlloSure Heart contributed to growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $100 mln $95.25

Revenue mln (8

Analysts

)

Q3 Beat $0.28 $0.14 (6

Adjusted Analysts

EPS )

Q3 EPS $0.03

Q3 Beat $14.90 $7.48

Adjusted mln mln (6

Net Analysts

Income )

Q3 Net $1.70

Income mln

Q3 Beat $15.30 $7.93

Adjusted mln mln (6

EBITDA Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for CareDx Inc ( CDNA ) is $23.00, about 35.8% above its November 3 closing price of $14.77

* The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 16 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)